Cancer Database Query Results

Scientific Papers found: Click to Expand⟱

CUR,

Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS

vitro+vivo,

GC,

AGS

mice

vitro+vivo,

GC,

HGC27

ROS↑, NRF2↑, eff↓, eff↑,

411-

CUR,

Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway

in-vitro,

BC,

MDA-MB-231

HH↓, EMT↓, Gli1↓,

412-

CUR,

Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

ROS↑, PTP1B↓,

477-

CUR,

Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells

in-vitro,

Cerv,

SiHa

5, 15, 30 and 50 µM, 6, 12, 24 and 48 h

TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, CycB/CCNB1↓, CDC25↓, ROS↑, p62↑, LC3‑Ⅱ/LC3‑Ⅰ↑, cl‑Casp3↑, cl‑PARP↑, P53↑, P21↑,

485-

CUR,

PDT,

Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin

in-vitro,

Melanoma,

1.25–3.12 μM

Skin Keratinocytes

NF-kB↓, Casp8↑, Casp9↑, p‑Akt↓, p‑ERK↓,

484-

CUR,

PDT,

Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light

in-vitro,

Melanoma,

0.2-1 microg/ml

skin keratinocytes

Cyt‑c↑, Casp9↑, Casp8↑, NF-kB↓, EGFR↓,

483-

CUR,

PDT,

Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin

in-vivo,

NA,

A431

0.2–1 μg/ml

mice

TumVol↓, TumCP↓, Apoptosis↑,

482-

CUR,

PDT,

The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro

in-vitro,

Bladder,

RT112

0.1 to 0.4 μg/ml

in-vitro,

Bladder,

UMUC3

Apoptosis↑, TumCG↓, TumCP↓,

481-

CUR,

CHr,

Api,

Flavonoid-induced glutathione depletion: Potential implications for cancer treatment

in-vitro,

Liver,

A549

in-vitro,

Pca,

PC3

in-vitro,

AML,

HL-60

GSH↓, mtDam↑, MMP↓, Cyt‑c↑,

480-

CUR,

Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells

in-vitro,

GBM,

SNB19

10, 15, 20 and 25 µM, 48 and 72 h

TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, NEDD9↓, NOTCH1↓, p‑Akt↓,

415-

CUR,

Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis

vitro+vivo,

BC,

MDA-MB-231

5, 10, 20 and 50 μM, 24 h; 25 g/kg, 4 weeks

mice

PSMB5↓, CT-I↓, miR-142-3p↑, EP300↓,

478-

CUR,

Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells

in-vitro,

Cerv,

SiHa

20 µM, 72 h

EMT↓, N-cadherin↓, Vim↓, Slug↓, Zeb1↓, PIR↓, Pirin↓, E-cadherin↑,

414-

CUR,

Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells

in-vitro,

BC,

MCF-7

114 μM

in-vitro,

BC,

MDA-MB-231

Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, GSH↓, HO-1↑, NRF2↑, GPx↓, ROS↑, Iron↑, GPx4↓, HSP70/HSPA5↑, ATFs↑, CHOP↑, MDA↑, FTL↑, FTH1↑, BACH1↑, REL↑, USF1↑, NFE2L2↑,

437-

CUR,

Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids

vitro+vivo,

CRC,

TCO1

0.6, 2, 6 and 20 µg/mL, 72 h; 20 mg/day, 21 days

vitro+vivo,

CRC,

TCO2

cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,

436-

CUR,

Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti‐lung cancer cell invasion

in-vitro,

Lung,

A549

10, 20 and 40 μM, 12, 24 and 48 h

miR-25-5p↓, miR-330-5p↑, MAPK↓, Wnt↓,

435-

CUR,

Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway

in-vitro,

Lung,

A549

5, 10, 20 and 40 μM, 24, 48, 72 and 96 h

Apoptosis↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1↑, p62↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, p‑mTOR↓,

434-

CUR,

Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad

in-vitro,

Lung,

A549

25, 50 and 100 μM, 48h

14-3-3 proteins↓, p‑BAD↓, p‑Akt↓, Akt↓, cl‑Casp9↑, cl‑PARP↑,

433-

CUR,

Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression

in-vitro,

Lung,

A549

1, 2, 5, 10 and 20 μM, 24 and 48 h

E-cadherin↓, Vim↓, Slug↓, N-cadherin↓, Snail↓, MMP9↓, EMT↓,

432-

CUR,

Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells

in-vitro,

Lung,

H446

5, 10, 15 and 20 μM, 24 and 48 h

Bcl-2↓, cycF↓, LOX1↓, VEGF↓, MRGPRF↓, BAX↑, Cyt‑c↑, miR-548ah-5p↑,

431-

CUR,

Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ

in-vitro,

Lung,

A549

5, 25, 125 and 250 nM, 24, 48 and 72 h

in-vitro,

Lung,

H1299

ALDH1A1↓, CD133↓, EpCAM↓, OCT4↓, TAZ↓, Hippo↑, p‑TAZ↑,

430-

CUR,

Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling

vitro+vivo,

Lung,

A549

50, 100 and 150 μM, 48 h; 100 mg/kg, 3 weeks

mice

PTEN↑, MEG3↑,

457-

CUR,

Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling

in-vitro,

GC,

SGC-7901

10, 20 and 40 μM, 24 h

in-vitro,

GC,

BGC-823

TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,

438-

CUR,

Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats

vitro+vivo,

CRC,

CC531

15, 20, 25 and 30 µM, 24, 48 and 72 h; 200 mg/kg/day, 28 days

TumCP↓, TumVol↓, Albumin↑, ALP↑, AST↑, ALAT↑, cholinesterase↓,

417-

CUR,

Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression

vitro+vivo,

BC,

MCF-7

20 and 40 µM, 48 h; 100 mg/kg/2 days, 21 days

mice

vitro+vivo,

BC,

MDA-MB-231

vitro+vivo,

BC,

MDA-MB-468

EZH2↓, DLC1↑, cycA1/CCNA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,

420-

CUR,

Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT

in-vitro,

BC,

MCF-7

10, 15, 20, 25, 30, 35 and 40 µM, 24 and 48 h

in-vitro,

BC,

MDA-MB-231

Vim↓, Fibronectin↓, β-catenin/ZEB1↓, E-cadherin↓, CD44↑, CD24↓, OCT4↓, Nanog↓, SOX2↓,

422-

CUR,

Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines

in-vitro,

BC,

HCC-38

5 and 10 µM, 3 days

in-vitro,

BC,

T47D

BRCA1↑, TET1↑, DNMT3A↑, DNMT1↓, SNCG↓, miR-29b↓, miR-29b↑,

423-

CUR,

Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells

in-vitro,

BC,

MCF-7

5, 10 and 25 µM, 48 h

more efficient in MDA- MB-231 cells than MCF-7 cells owing to its greater inhibitory efficacy in the LPS- enhanced TLR4 signaling pathway.

in-vitro,

BC,

MDA-MB-231

TLR4↓, IRF3↓, IFN-γ↓, TRIF↓,

424-

CUR,

Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells

in-vitro,

BC,

MCF-7

5, 10, 15, 20, 25 and 30 µM, 24, 48 and 72 h

in-vitro,

BC,

MDA-MB-231

Src↓, p‑STAT1↓, p‑Akt↓, p‑p44↓, p‑p42↓, RAS↓, Raf↓, Vim↓, β-catenin/ZEB1↓, P53↓, Bcl-2↓, Mcl-1↓, PIAS-3↑, SOCS-3↑, SOCS1↑, ROS↑, NF-kB↓, PAO↑, SSAT↑, P21↑, Bak↑,

425-

CUR,

Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells

in-vitro,

BC,

T47D

10 and 30 µM, 24 and 48 h

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

in-vitro,

BC,

MDA-MB-468

CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,

426-

CUR,

Use of cancer chemopreventive phytochemicals as antineoplastic agents

in-vitro,

BC,

MDA-MB-231

5 µM, 48 h

in-vitro,

BC,

CAL51

Bcl-2↓, ROS↑, BAX↑, RAD51↑, γH2AX↑,

427-

CUR,

Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway

in-vitro,

Lung,

H1299

10, 20 and 40 μM, 24 h

in-vitro,

Lung,

H460

vitro+vivo,

Lung,

A549

 50 mg/kg, 22 days

ITGB1↓, circ-PRKCA↓, miR-384↑,

429-

CUR,

TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression

in-vitro,

Lung,

H1299

2.5, 5 and 7.5 μM, 48 h

in-vitro,

Lung,

A549

TAp63α↑, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, miR-19b↓,

447-

CUR,

OXA,

Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway

vitro+vivo,

CRC,

HCT116

1, 2, 4, 8, 16, 32 and 64 μM, 48 h; 60 mg/kg, 3 weeks

4uM(Cur)+10uM(OXA)

p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,

456-

CUR,

Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells

vitro+vivo,

GC,

SGC-7901

50 μM, 24, 48 and 96 h

miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1/CCND1↓,

455-

CUR,

Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin

in-vitro,

GC,

SGC-7901

10, 20, 40 and 80 µM, 48 h

Shh↓, Gli1↓, FOXM1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,

454-

CUR,

Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway

in-vitro,

GC,

MGC803

5, 10, 15, 20, 40 and 60 μM, 24, 48 and 72 h

TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,

453-

CUR,

Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells

in-vitro,

GC,

AGS

10,- 100 µM, 24, 48 and 72 h; 50 mg/kg, 6weeks

Bcl-2↓, survivin↓, BAX↑, TumCCA↑,

452-

CUR,

Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells

vitro+vivo,

HNSCC,

SCC9

0, 25, 10, 5, 2.5, 1.25 and 0.75 μM, 24 and 48 h

41uM

vitro+vivo,

HNSCC,

FaDu

vitro+vivo,

HNSCC,

HaCaT

TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,

451-

CUR,

The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer

vitro+vivo,

HNSCC,

SCC15

1, 2, 5, 10, 20, 40 and 80 µM, 1, 3, 6, 12 and 24 h; 50 mg/kg, 6 weeks

vitro+vivo,

HNSCC,

SNU1076

vitro+vivo,

HNSCC,

SNU1041

TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,

450-

CUR,

Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44

in-vitro,

CRC,

HCT116

2.5, 5, 10, 20 and 40 µM, 24 h

in-vitro,

CRC,

HCT8

TumCP↓, TumCMig↓, CD44↓, CSCs↓,

449-

CUR,

Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a

vitro+vivo,

CRC,

SW480

40 μM, 24 h; 200 mg/kg, 5 days

TumCP↓, β-catenin/ZEB1↓, TCF↓, miR-21↓, NKD2↑, miR-130a↓,

448-

CUR,

Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation

in-vitro,

CRC,

HT-29

15, 20 and 25 μM, 48 h

Apoptosis↑, TumCCA↑, p‑Akt↓, Akt↓, Bcl-2↓, p‑BAD↓, BAD↑, cl‑PARP↑, ROS↑, HSP27↑, Beclin-1↑, p62↑, GPx1↓, GPx4↓,

446-

CUR,

The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells

in-vitro,

CRC,

SW480

5, 10, 15, 20, 25, 30, and 50 μM, 48 and 72 h

IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,

445-

CUR,

Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway

in-vitro,

CRC,

HCT116

10 μM, 24 h

in-vitro,

CRC,

HCT8

in-vitro,

CRC,

SW480

in-vitro,

CRC,

SW-620

p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,

444-

CUR,

Cisplatin,

LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells

vitro+vivo,

CRC,

HCT8

10 μM, 48 h; 1 g/kg/week, 42 days

TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,

443-

CUR,

Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells

in-vitro,

CRC,

SW480

DNMT1↓, DNMT3A↓, N-cadherin↓, Vim↓, Wnt↓, Snail↓, Twist↓, β-catenin/ZEB1↓, E-cadherin↑, EMT↓, CDX2↓,

442-

CUR,

5-FU,

Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress

in-vitro,

CRC,

HCT116

0-40uM

Apoptosis↑, TumCP↓, TumCCA↑, TET1↑, NKD2↑, Wnt↓, EMT↓, Vim↑, E-cadherin↓, β-catenin/ZEB1↓, TCF↓, AXIN1↓,

441-

CUR,

Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p

in-vitro,

CRC,

HCT116

10, 20, 30 and 40 µM, 48 h

ERCC1↓, Bcl-2↓, GSTP1/GSTπ↓, MRP↓, P-gp↓, miR-409-3p↑, survivin↓,

440-

CUR,

Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells

vitro+vivo,

CRC,

SW480

10, 20, 30, 40, 50 and 60 µM, 24 h; 100 mg/kg/day, 3 weeks

vitro+vivo,

CRC,

HT-29

13.69 μM

NNMT↓, p‑STAT3↓, TumCP↓, TumCCA↑, ROS↑,

439-

CUR,

Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway

in-vitro,

CRC,

LGR5

LGR5(+) colorectal CSCs

Apoptosis↑, TumAuto↑, GP1BB↓, COL9A3↓, COMP↓, AGRN↓, ITGB4↓, LAMA5↓, COL2A1↓, ITGB6↓, LGR5↓, TFAP2A↓, ECM/TCF↓,

Showing Research Papers: 2651 to 2700 of 6604
Prev Page 54 of 133 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6604

Pathway results for Effect on Cancer / Diseased Cells:

Infection & Microbiome ⓘ

CD8+↑, 1, IRF3↓, 1,
Total Targets: 234

Pathway results for Effect on Normal Cells:

Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Cancer Database Query Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Metal & Cofactor Biology ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Kinase & Signal Transduction ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Cellular Microenvironment ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Infection & Microbiome ⓘ

Pathway results for Effect on Normal Cells:

Home Page